Infectious Disease Unit, Azienda Ospedaliera Universitaria di Modena, Largo del Pozzo 71, 41124, Modena, Italy.
Hematology Unit and Chair, Azienda Ospedaliera Universitaria di Modena, Modena, Italy.
Infection. 2023 Oct;51(5):1577-1581. doi: 10.1007/s15010-023-02039-2. Epub 2023 Apr 19.
People with hematologic malignancies have a significantly higher risk of developing severe and protracted forms of SARS-CoV-2 infection compared to immunocompetent patients, regardless of vaccination status.
We describe two cases of prolonged SARS-CoV-2 infection with multiple relapses of COVID-19 pneumonia in patients with follicular lymphoma treated with bendamustine and obinutuzumab or rituximab. The aim is to highlight the complexity of SARS-CoV-2 infection in this fragile group of patients and the necessity of evidence-based strategies to treat them properly.
Patients with hematological malignancies treated with bendamustine and anti-CD20 antibodies had a significant risk of prolonged and relapsing course of COVID-19. Specific preventive and therapeutic strategies should be developed for this group of patients.
与免疫功能正常的患者相比，血液系统恶性肿瘤患者罹患严重和持久的 SARS-CoV-2 感染的风险显著更高，无论其疫苗接种状态如何。
我们描述了两例滤泡性淋巴瘤患者在接受苯达莫司汀和奥滨尤妥珠单抗或利妥昔单抗治疗后，SARS-CoV-2 感染持续时间延长且 COVID-19 肺炎多次复发的病例。目的是强调在这群脆弱的患者中 SARS-CoV-2 感染的复杂性，以及制定基于证据的策略来对其进行适当治疗的必要性。
接受苯达莫司汀和抗 CD20 抗体治疗的血液系统恶性肿瘤患者 COVID-19 呈显著延长和复发病程的风险。应针对这群患者制定特定的预防和治疗策略。
